发明名称 5-ARYL-THIAZOL-2-YL-AMINE COMPOUNDS AND THEIR THERAPEUTIC USE
摘要 <p>The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain 5-aryl-thiazol-2-yl-amine compounds of the following formula (I) (for convenience, collectively referred to herein as "5AT2A compounds"), which, inter alia, inhibit LIM kinase (LIMK) activity. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit LIMK activity, and in the treatment of diseases and conditions that are mediated by LIMK, that are ameliorated by the inhibition of LIMK activity, etc., including proliferative conditions such as cancer (e.g., breast cancer, prostate cancer, melanoma, glioma, etc.), as well as vasodilation (including, e.g., hypertension, angina, cerebral vasospasm, and ischemia following subarachnoid hemorrhage), neurodegenerative disorders, atherosclerosis, fibrosis, and inflammatory diseases (including, e.g., Crohn's disease and chronic obstructive pulmonary disease (COPD)), and glaucoma (also known as ocular hypertension). (Formula (I))</p>
申请公布号 WO2015025172(A1) 申请公布日期 2015.02.26
申请号 WO2014GB52574 申请日期 2014.08.22
申请人 CHARLES, MARK DAVID;BROOKFIELD, JOANNA LOLA;EKWURU, CHUKUEMEKA TENNYSON;STOCKLEY, MARTIN LEE 发明人 CHARLES, MARK DAVID;BROOKFIELD, JOANNA LOLA;EKWURU, CHUKUEMEKA TENNYSON;STOCKLEY, MARTIN LEE
分类号 C07D417/04;A61K31/427;A61P9/00;A61P11/00;A61P25/00;A61P35/00;C07D417/14 主分类号 C07D417/04
代理机构 代理人
主权项
地址